Abstract
The cardiac specific troponins (cTn) are the preferred biomarkers for the diagnosis of myocardial infarction. They are measured quantitatively in the serum. The use of highly sensitive cTn assays made the measurement of other markers (such as myoglobin, CK-MB mass, fatty acid binding protein) redundant, because they confer no added diagnostic benefit. To date, highly sensitive cTn assays are available only on two POCT benchtop devices. Laboratory assays used in heart failure include the use of BNP and NT-pro-BNP markers as recommended by the European and American Associations for the screening and diagnosis of heart failure. POCT methods are now becoming capable of measuring these cardiac markers with high sensitivity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Altintas Z, Fakanya W, Tothill I (2014) Cardiovascular disease detection using bio-sensing techniques. Talanta 128: 177–186
Amundson B, Apple F (2015) Cardiac troponin assays: a review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction. Clin Chem Lab Med 53: 665–676
Antman EM, Anbe DT, Armstrong PW et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 44: 671–719; erratum in: J Am Coll Cardiol 2005; 45: 1376
Anwaruddin S, Lloyd-Jones DM, Baggish A et al. (2006) Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47: 91–97
Apple FS, Wu AHB, Jaffe AS (2002) European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials. J Am Heart 144: 981–986
AWMF online (2015) Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Leitlinien Angiologie 2015; www.leitlinien.net. Last revised: 10/2015
Braunwald E, Antman EM, Beasley JW et al. (2002) ACC/AHA 2002 guideline update for the management of patients with unstable angina and non- ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40:1366–1374
Christenson RH on behalf of the Committee on Evidence Based Laboratory Medicine of the International Federation for Clinical Chemistry Laboratory Medicine (2007) Evidence-based laboratory medicine – a guide for critical evaluation of in vitro laboratory testing. Ann Clin Biochem 44: 111–130
Collinson P, Goodacre S, Gaze D, Gray A (2012) Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial. Heart 98: 312–318
Goodacre S, Bradburn M, Fitzgerald P, Cross E, Collinson P, Gray A, Hall AS (2011) The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technol Assess 15 (23): 1–102
Hunt SA, Abraham WT, Chin MH et al. (2005) American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure), developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: 154–235
Karakas M, Januzzi JL Jr, Meyer J, Lee H, Schlett CL, Truong QA et al. (2011) Copeptin does not add diagnostic information to high-sensitivity troponin T in low- to intermediate-risk patients with acute chest pain: Results from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem 57:1137–1145
Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E et al. (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877
Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM et al. (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106
Korley FK, Jaffe AS (2013) Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol 61: 1753–1758
Lee-Lewandroski E, Januzzi JJ, Grisson R, Mohammed A, Lewandrowski G, Lewandrowski K (2011) Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction. Arch Pathol Lab Med 135: 459–463
McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83: 596–602
Panteghini M, Pagani F, Yeo KT et al. (2004) Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 50: 327–332
Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG et al. (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–68
Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527–1560
Ryan RJ, Lindsell CJ, Hollander JE, O’Neil B, Jackson R, Schreiber D, Christenson R, Gibler WB (2009) A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med 53:321–328
Roffi M et al., for the Task Force of the European Society of Cardiology (ESC) (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal) 37: 267–315
Sandoval Y, Apple FS (2014) The global need to define normality: the 99th percentile value of cardiac troponin. Clin Chem 60: 455–462
Tang WH, Francis GS, Morrow DA et al. (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116: 99–109
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction (2012) Third universal definition of myocardial infarction. Glob Heart 7(4):275–295
Vafaie M, Biener M, Mueller M, Abu Sharar H, Hartmann O, Hertel S, Katus HA, Giannitsis E (2015) Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction – A pilot study. Int J Cardiol 198:26–30
Venge P, Öhberg C, Flodin M, Lindahl B (2010) Early and late outcome prediction of death in the emergency room setting by point-of-care and laboratory assays of cardiac troponin I. Am Heart J 160: 835–841
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Germany, part of Springer Nature
About this chapter
Cite this chapter
Giannitsis, E., Schimke, I., Luppa, P.B., Peetz, D. (2018). Diagnosing cardiovascular diseases. In: Luppa, P.B., Junker, R. (eds) Point-of-Care Testing. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54497-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-662-54497-6_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-54496-9
Online ISBN: 978-3-662-54497-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)